Focus on Psychosis

Page 2

Recently published articles about Focus on Psychosis

JCP
Inflammatory Features in Prodromal Psychosis
Original Research

July 17, 2023

This study suggests that niacin response tests should be considered in early psychosis identification and prediction.
, , , et al
JCP
Generalizability of RCTs in First-Episode Schizophrenia
Original Research

March 29, 2023

First-episode schizophrenia patients with suicidal ideation and substance use disorder are often excluded from clinical trials. Omitting them does not affect key outcome measures but excludes many potential subjects.
, , , et al
JCP
Neighborhood Vulnerability in First-Episode Psychosis
Original Research

March 13, 2023

Psychosocial difficulties in people with first-episode psychosis could be related to a lack of resources in the area where they live.
, , , et al
JCP
Predictors for Initiation of LAIs in Individuals With Early-Phase Schizophrenia
Original Research

February 13, 2023

Initiation of LAIs was predicted by greater switching of oral antipsychotics and more ED visits. LAIs are often used to respond to relapse rather than prevent it.
, , , et al
JCP
Antipsychotic Dose and Weight Gain
Meta-Analysis

February 8, 2023

Although effects on weight gain have been explored for several antipsychotics, the role of dose in producing these effects has not been widely studied. This meta-analysis examined the association...
, , , et al
JCP
Telehealth of CSC in Early Psychosis During COVID-19
Original Research

November 30, 2022

As the COVID-19 pandemic emerged in 2020, access to in-person clinical care was restricted. This study explored if transition of coordinated specialty care to telehealth for psychosis patients allowed...
, , , et al
JCP
Economic Burden of Schizophrenia in the US
Original Research

October 10, 2022

Schizophrenia is associated with significant economic burden, not only for patients but also for families, other caregivers, and the wider society. This study analyzed recent data and literature to...
, , , et al
JCP
Add-on Pramipexole for Schizophrenia
Original Research

August 1, 2022

Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. This 16-week, multicenter, double-blind, randomized, placebo-controlled study was conducted to test...
, , , et al
JCP
Long-term Outcomes of Early Use of LAIs in Schizophrenia
Original Research

June 1, 2022

Using data from the Taiwan National Health Insurance Research Database, the authors compared long-term effectiveness of switching to long-acting injectable antipsychotics versus remaining on oral antipsychotics.
, ,
JCP
Effects of a Digital Medicine System on Psychiatric Hospitalization Rates for Adults With Schizophrenia
Original Research

April 11, 2022

This clinical trial investigated whether hospitalization rates improved when patients with schizophrenia were treated via a digital medicine system (aripiprazole tablets with sensor) versus oral standard-of-care therapy.
, , , et al
JCP
Association of Higher ALFF and Suicidal Ideation in BD
Original Research

March 30, 2022

Higher amplitude of low frequency fluctuation in the right hippocampus and thalamus has been found to be associated with suicidal ideation in major depressive disorder. The present study evaluated...
, , , et al
JCP
Antipsychotic Prescription in Prodromal Psychosis
Original Research

March 21, 2022

Although antipsychotics are not considered the first option to treat individuals at clinical high risk (CHR) for psychosis, use of these medications is common. This study explored characteristics of...
, , , et al

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe